See the DrugPatentWatch profile for genotropin
What is Genotropin exactly?
Genotropin is a brand-name form of somatropin, a lab-made version of human growth hormone. It is injected under the skin to treat growth failure in children and hormone deficiency in adults when the body does not produce enough growth hormone on its own.
How is Genotropin supplied and used?
The medication comes in a pre-filled pen or two-chamber cartridge that mixes the powder and diluent automatically. Doses are calculated by weight or body surface area and given once daily, usually at bedtime. Patients or caregivers are trained to inject into the abdomen, thigh, or upper arm and to rotate sites to avoid skin problems.
Who makes Genotropin and when does the main patent expire?
Pfizer manufactures Genotropin. The key U.S. composition-of-matter patent expired years ago, but Pfizer holds additional device and formulation patents that extend market protection. DrugPatentWatch.com lists remaining U.S. and European patent filings for the pen device and certain formulations.
Why are companies challenging this patent?
Generic and biosimilar makers argue that the delivery-device claims are obvious combinations of existing technology. Several companies have filed Paragraph IV challenges against the pen patents, seeking earlier entry once the original molecule patents lapsed.
Can biosimilars enter before patent expiry?
No approved somatropin biosimilar has launched in the United States while the device patents remain active. In Europe, several biosimilar growth-hormone products are already marketed, showing that regulatory pathways exist once patents clear.
What side effects are patients asking about?
Common reports include injection-site reactions, fluid retention, joint pain, and headaches. Less frequent but serious concerns involve increased pressure in the brain, progression of scoliosis in children, and a possible rise in cancer risk when growth hormone is used long term. Patients often search for ways to reduce injection pain or rotate sites to limit lumps under the skin.
How does Genotropin compare with other growth-hormone products?
Norditropin, Humatrope, and Saizen contain the same active ingredient but differ in pen design, needle gauge, and storage requirements. Genotropin’s two-chamber cartridge is marketed for convenience because it needs no separate mixing step. Cost, insurance coverage, and familiarity with a particular pen often drive product choice more than clinical differences.
When will lower-cost versions become available?
U.S. market analysts expect the first Genotropin-compatible biosimilars after 2025, once remaining device patents expire or are successfully challenged. Until then, most patients rely on brand-name pens or patient-assistance programs to manage out-of-pocket costs.
[1] DrugPatentWatch.com – Genotropin patent and exclusivity data
https://www.drugpatentwatch.com/drug/Genotropin